Analysis Hisamitsu Pharmaceutical Co., Inc. (4530)
6/3/2024
Analysis of Hisamitsu Pharmaceutical Co., Inc. (4530)
Hisamitsu Pharmaceutical Co., Inc. is a Japanese pharmaceutical company that specializes in developing and manufacturing pharmaceutical products, particularly transdermal patches.Looking at the recent financial data provided, we can see that the stock price of Hisamitsu Pharmaceutical Co., Inc. has been fluctuating. The Relative Strength Index (RSI) indicator shows that the stock has been in overbought territory, indicating a possible reversal in the short term.
The Moving Average Convergence Divergence (MACD) indicator shows a positive value, suggesting a bullish trend. However, the MACD histogram has been decreasing, indicating a potential weakening of the bullish momentum.
Overall, it seems that Hisamitsu Pharmaceutical Co., Inc. is experiencing some volatility in its stock price, with mixed signals from the technical indicators. Investors may want to closely monitor the stock for any potential changes in trend.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a slight improvement from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates show a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided:- The current year growth rate is 7.6%
- The next quarter growth rate is 5.1%
- The current quarter growth rate is 5.1%
- The next year growth rate is 9.7%
- The next 5 years compound annual growth rate (CAGR) is 9.7%
- The past 5 years compound annual growth rate (CAGR) is 20.1%
It can be observed that the company is expected to experience a higher growth rate in the future compared to the current and past performance. The next year and next 5 years are projected to have similar growth rates, indicating sustained growth over the medium term. However, the past 5 years had a significantly higher growth rate compared to the future estimates, suggesting a potential slowdown in growth.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median forecast above the current price. However, there is a wide range of estimates, from a low of $164 to a high of $275, indicating some uncertainty in the predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results from February 27, 2025, were related to the Transfer Agent. The results from January 31, 2025, were reported After Hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an EPS estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio and a high total debt to equity ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and it has shown a positive return on assets and return on equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock price summary shows volatility with a beta of 1.264 and a fluctuation between the fifty-two-week low and high.
Valuation metrics reveal a high PEG ratio and price to book ratio, with the company being relatively expensive based on its forward and trailing P/E ratios. The enterprise value, market capitalization, and other ratios indicate the company's valuation in the market.
Lastly, dividends and splits information shows the company's dividend history, payout ratio, and dividend yield. The company has a regular dividend payment schedule and has undergone a stock split in the past.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2023: Sales of $383,285,000,000
2. Fiscal Year 2022: Sales of $394,328,000,000
3. Fiscal Year 2021: Sales of $365,817,000,000
4. Fiscal Year 2020: Sales of $274,515,000,000
From these figures, we can observe the following trends:
- The company experienced a decrease in revenue from FY 2022 to FY 2023.
- Prior to FY 2023, there was a general trend of increasing revenue over the years.
- The highest revenue was recorded in FY 2022.
These trends can provide insights into the company's performance and may indicate areas that require further analysis or attention.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include acquisitions, capital expenditures, and the sale/purchase of investments.
7. The company has been utilizing stock-based compensation as part of its operations.
8. Overall, the cash flow statement reflects the financial health and strategic decisions of the company over the years.
MACD of 4530
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
